Cowen And Company, LLC Pro Qr Therapeutics N.V. Call Options Transaction History
Cowen And Company, LLC
- $3.88 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PRQR
# of Institutions
73Shares Held
22.6MCall Options Held
37.7KPut Options Held
21.3K-
Privium Fund Management B.V.4.99MShares$11.3 Million3.12% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.63MShares$8.19 Million0.01% of portfolio
-
Affinity Asset Advisors, LLC New York, NY2.83MShares$6.38 Million1.38% of portfolio
-
Ubs Group Ag2.31MShares$5.22 Million0.0% of portfolio
-
Platinum Investment Management LTD Sydney Australia 2000, C31.54MShares$3.48 Million0.25% of portfolio
About ProQR Therapeutics N.V.
- Ticker PRQR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,362,096
- Market Cap $161M
- Description
- ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...